LeMaitre Vascular (LMAT) Hit by Profit Taking

3 weeks ago 25

Soumya Eswaran

Thu, August 6, 2026 astatine 7:51 AM CDT 3 min read

Conestoga Capital Advisors, an plus absorption company, released its second-quarter 2026 capitalist letter. A transcript of the missive tin be downloaded here. The missive reports a affirmative marketplace displacement towards Small Caps, with the Russell 2000 Index achieving its champion archetypal fractional since 1991 and the Russell 2000 Growth Index up 25.7% successful Q2, fueled by AI enthusiasm and semiconductor stocks. However, marketplace enactment was uneven, mirroring the Tech Bubble, with high-beta stocks outperforming portion high-quality companies lagged, which impacted Conestoga's quality-focused strategies. Management expressed assurance successful semipermanent outcomes, noting that speculative enactment won't past arsenic monetary argumentation tightens and marketplace breadth improves. The steadfast remains committed to high-quality maturation businesses, expecting these to regain favour arsenic enactment broadens. The Conestoga Small Cap Composite returned 14.32% net-of-fees successful the 2nd quarter, with 25.71% for the Russell 2000 Growth Index. Narrow Index enactment wounded the comparative results, but it besides hid Composite improvements. In addition, delight cheque the Strategy's apical 5 holdings to cognize its champion picks successful 2026.

In its Q2 2026 capitalist letter, Conestoga Capital Advisors highlighted LeMaitre Vascular, Inc. (NASDAQ:LMAT). LeMaitre Vascular, Inc. (NASDAQ:LMAT) is simply a aesculapian instrumentality institution focusing connected the manufacturing and improvement of products and services for vascular surgery. On August 5, 2026, LeMaitre Vascular, Inc. (NASDAQ:LMAT) closed astatine $79.00 per share, reflecting a marketplace capitalization of $1.81 billion. LeMaitre Vascular, Inc. (NASDAQ:LMAT) posted a one-month instrumentality of -22.85%, portion its shares mislaid 16.19% implicit the past 52 weeks.

Conestoga Capital Advisors stated the following regarding LeMaitre Vascular, Inc. (NASDAQ:LMAT) successful its Q2 2026 capitalist letter:

"LeMaitre Vascular, Inc. (NASDAQ:LMAT) delivered different beardown cardinal quarter, reporting 10% integrated gross growth, gross margins of 72.1%, and adjusted EPS of $0.68, exceeding the statement estimation of $0.66. Despite these coagulated operating results, the shares declined pursuing the net merchandise arsenic investors took profits successful 1 of the aesculapian instrumentality sector's strongest performers. Prior to reporting first-quarter results connected May 5, 2026, LMAT shares had appreciated astir 38% year-to-date. We proceed to judge the institution is good positioned to make charismatic gross and net maturation implicit the coming years, supported by its differentiated vascular merchandise portfolio and accordant execution."

Read Entire Article